Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTA NASDAQ:DNLI NASDAQ:IBRX NASDAQ:MGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$20.85+15.6%$16.09$9.60▼$20.87$2.79B1.471.00 million shs3.40 million shsDNLIDenali Therapeutics$15.36-0.9%$14.58$10.57▼$33.33$2.25B1.231.48 million shs1.55 million shsIBRXImmunityBio$2.57+6.6%$2.56$1.83▼$7.48$2.43B0.37.95 million shs21.60 million shsMGTXMeiraGTx$7.65+2.4%$7.91$3.86▼$8.98$615.44M1.29513,967 shs360,134 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals+14.62%+7.39%+5.93%+48.76%+26.08%DNLIDenali Therapeutics+0.45%+1.51%+11.03%+1.57%-38.61%IBRXImmunityBio+0.42%+2.99%-1.23%-27.84%-28.70%MGTXMeiraGTx-2.86%+2.33%-5.20%+8.89%+92.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTACentessa Pharmaceuticals$20.85+15.6%$16.09$9.60▼$20.87$2.79B1.471.00 million shs3.40 million shsDNLIDenali Therapeutics$15.36-0.9%$14.58$10.57▼$33.33$2.25B1.231.48 million shs1.55 million shsIBRXImmunityBio$2.57+6.6%$2.56$1.83▼$7.48$2.43B0.37.95 million shs21.60 million shsMGTXMeiraGTx$7.65+2.4%$7.91$3.86▼$8.98$615.44M1.29513,967 shs360,134 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTACentessa Pharmaceuticals+14.62%+7.39%+5.93%+48.76%+26.08%DNLIDenali Therapeutics+0.45%+1.51%+11.03%+1.57%-38.61%IBRXImmunityBio+0.42%+2.99%-1.23%-27.84%-28.70%MGTXMeiraGTx-2.86%+2.33%-5.20%+8.89%+92.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTACentessa Pharmaceuticals 3.08Buy$31.4550.86% UpsideDNLIDenali Therapeutics 3.12Buy$33.50118.10% UpsideIBRXImmunityBio 3.20Buy$10.75318.29% UpsideMGTXMeiraGTx 3.00Buy$24.00213.73% UpsideCurrent Analyst Ratings BreakdownLatest MGTX, CNTA, DNLI, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025DNLIDenali TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight9/8/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.009/3/2025CNTACentessa PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025CNTACentessa PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$31.008/29/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$40.008/26/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/18/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$33.00 ➝ $30.008/15/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.008/14/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.008/12/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.008/5/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTACentessa Pharmaceuticals$6.85M407.59N/AN/A$3.05 per share6.84DNLIDenali TherapeuticsN/AN/AN/AN/A$8.53 per shareN/AIBRXImmunityBio$14.74M164.81N/AN/A($0.57) per share-4.51MGTXMeiraGTx$33.28M18.49N/AN/A$0.87 per share8.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTACentessa Pharmaceuticals-$235.76M-$1.79N/AN/AN/AN/A-40.39%-29.87%11/11/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.80N/AN/AN/AN/A-40.79%-36.39%11/5/2025 (Estimated)IBRXImmunityBio-$413.56M-$0.48N/AN/AN/A-648.57%N/A-113.86%11/11/2025 (Estimated)MGTXMeiraGTx-$147.79M-$2.04N/A20.13N/A-415.39%-314.44%-63.28%11/12/2025 (Estimated)Latest MGTX, CNTA, DNLI, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MGTXMeiraGTx-$0.52-$0.48+$0.04-$0.48$8.00 million$3.69 million8/12/2025Q2 2025CNTACentessa Pharmaceuticals-$0.35-$0.38-$0.03-$0.38$0.63 millionN/A8/11/2025Q2 2025DNLIDenali Therapeutics-$0.74-$0.72+$0.02-$0.72$5.64 millionN/A8/5/2025Q2 2025IBRXImmunityBio-$0.10-$0.10N/A-$0.10$21.95 million$26.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTACentessa PharmaceuticalsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTACentessa Pharmaceuticals0.3210.1110.12DNLIDenali Therapeutics0.0110.2710.27IBRXImmunityBioN/A4.113.98MGTXMeiraGTx26.290.880.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTACentessa Pharmaceuticals82.01%DNLIDenali Therapeutics92.92%IBRXImmunityBio8.58%MGTXMeiraGTx67.48%Insider OwnershipCompanyInsider OwnershipCNTACentessa Pharmaceuticals7.09%DNLIDenali Therapeutics12.50%IBRXImmunityBio76.79%MGTXMeiraGTx7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTACentessa Pharmaceuticals200133.91 million124.42 millionOptionableDNLIDenali Therapeutics430146.21 million127.94 millionOptionableIBRXImmunityBio590945.26 million219.39 millionOptionableMGTXMeiraGTx30080.45 million74.41 millionOptionableMGTX, CNTA, DNLI, and IBRX HeadlinesRecent News About These CompaniesAdage Capital Partners GP L.L.C. Has $38.20 Million Stake in MeiraGTx Holdings PLC $MGTXSeptember 6 at 6:32 AM | marketbeat.comMeiraGTx Holdings PLC $MGTX Shares Purchased by 683 Capital Management LLCSeptember 4, 2025 | marketbeat.comNuveen LLC Makes New Investment in MeiraGTx Holdings PLC $MGTXSeptember 3, 2025 | marketbeat.comWellington Management Group LLP Has $1.40 Million Stock Holdings in MeiraGTx Holdings PLC $MGTXSeptember 2, 2025 | marketbeat.comLong Focus Capital Management LLC Boosts Stock Position in MeiraGTx Holdings PLC $MGTXSeptember 1, 2025 | marketbeat.comInvesco Ltd. Raises Stake in MeiraGTx Holdings PLC $MGTXSeptember 1, 2025 | marketbeat.comRussell Investments Group Ltd. Has $1.05 Million Stake in MeiraGTx Holdings PLC $MGTXAugust 31, 2025 | marketbeat.comAffinity Asset Advisors LLC Makes New Investment in MeiraGTx Holdings PLC $MGTXAugust 28, 2025 | marketbeat.comWorth Venture Partners LLC Invests $217,000 in MeiraGTx Holdings PLC $MGTXAugust 27, 2025 | marketbeat.comMeiraGTx Holdings PLC $MGTX Shares Acquired by Erste Asset Management GmbHAugust 23, 2025 | marketbeat.comMeiraGTx (NASDAQ:MGTX) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPSAugust 17, 2025 | marketbeat.comMeiraGTx's (MGTX) Buy Rating Reiterated at Chardan CapitalAugust 17, 2025 | marketbeat.comMeiraGTx Holdings PLC Reports Q2 2025 Earnings: EPS of -$0. ...August 16, 2025 | gurufocus.comMeiraGTx Reports Progress in Genetic Medicines DevelopmentAugust 15, 2025 | msn.comMeiraGTx reports Q2 EPS (48c) vs (76c) last yearAugust 14, 2025 | msn.comMeiraGTx Sales Jump 1,133 PercentAugust 14, 2025 | aol.comAMeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue EstimatesAugust 14, 2025 | zacks.comMeiraGTx Reports Second Quarter 2025 Financial and Operational ResultsAugust 14, 2025 | globenewswire.com83,049 Shares in MeiraGTx Holdings PLC (NASDAQ:MGTX) Purchased by Informed Momentum Co LLCAugust 14, 2025 | marketbeat.comMeiraGTx Holdings plc's (NASDAQ:MGTX) large institutional owners must be happy as stock continues to impress, up 25% over the past weekJuly 9, 2025 | finance.yahoo.comInsider Sell Alert: Alexandria Forbes Sells 47,500 Shares of MeiraGTx Holdings PLCJuly 8, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGTX, CNTA, DNLI, and IBRX Company DescriptionsCentessa Pharmaceuticals NASDAQ:CNTA$20.85 +2.82 (+15.64%) Closing price 04:00 PM EasternExtended Trading$20.62 -0.24 (-1.13%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Denali Therapeutics NASDAQ:DNLI$15.36 -0.14 (-0.90%) Closing price 04:00 PM EasternExtended Trading$15.04 -0.32 (-2.05%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.ImmunityBio NASDAQ:IBRX$2.57 +0.16 (+6.64%) Closing price 04:00 PM EasternExtended Trading$2.58 +0.01 (+0.19%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.MeiraGTx NASDAQ:MGTX$7.65 +0.18 (+2.41%) Closing price 04:00 PM EasternExtended Trading$7.64 -0.01 (-0.07%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
